Literature DB >> 23234640

Evaluation and treatment of lower urinary tract symptoms in older men.

P Abrams1, C Chapple, S Khoury, C Roehrborn, J de la Rosette.   

Abstract

PURPOSE: The 6th International Consultation on New Developments in Prostate Cancer and Prostate Diseases met from June 24-28, 2005 in Paris, France to review new developments in benign prostatic disease.
MATERIALS AND METHODS: A series of committees were asked to produce recommendations on the evaluation and treatment of lower urinary tract symptoms in older men. Each committee was asked to base recommendations on a thorough assessment of the available literature according to the International Consultation on Incontinence level of evidence and grading system adapted from the Oxford system.
RESULTS: The Consultation endorsed the appropriate use of the current terminology lower urinary tract symptoms/benign prostatic hyperplasia/benign prostate enlargement and benign prostatic obstruction, and recommended that terms such as "clinical benign prostatic hyperplasia" or "the benign prostatic hyperplasia patient" be abandoned, and asked the authorities to endorse the new nomenclature. The diagnostic evaluation describes recommended and optional tests, and in general places the focus on the impact (bother) of lower urinary tract symptoms on the individual patient when determining investigation and treatment. The importance of symptom assessment, impact on quality of life, physical examination and urinalysis is emphasized. The frequency volume chart is recommended when nocturia is a bothersome symptom to exclude nocturnal polyuria. The recommendations are summarized in 2 algorithms, 1 for basic management and 1 for specialized management of persistent bothersome lower urinary tract symptoms.
CONCLUSIONS: The use of urodynamics and transrectal ultrasound should be limited to situations in which the results are likely to benefit the patient such as in selection for surgery. It is emphasized that imaging and endoscopy of the urinary tract have specific indications such as dipstick hematuria. Treatment should be holistic, and may include conservative measures, lifestyle interventions and behavioral modifications as well as medication and surgery. Only treatments with a strong evidence base for their clinical effectiveness should be used.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23234640     DOI: 10.1016/j.juro.2012.11.021

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

Review 1.  A critical review of recent clinical practice guidelines on the diagnosis and treatment of non-neurogenic male lower urinary tract symptoms.

Authors:  Michael Erlano Chua; Jonathan Mendoza; Manuel See; Ednalyn Esmena; Dean Aguila; Jan Michael Silangcruz; Buenaventura Jose Reyes; Saturnino Luna; Marcelino Morales
Journal:  Can Urol Assoc J       Date:  2015 Jul-Aug       Impact factor: 1.862

2.  Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort.

Authors:  Amar Bhindi; Bimal Bhindi; Girish S Kulkarni; Robert J Hamilton; Ants Toi; Theodorus H van der Kwast; Andrew Evans; Alexandre R Zlotta; Antonio Finelli; Neil E Fleshner
Journal:  Can Urol Assoc J       Date:  2017 Jan-Feb       Impact factor: 1.862

3.  BPH nomogram using IPSS, prostate volume, peak flow rate, PSA and median lobe protrusion for predicting the need for intervention: development and internal validation.

Authors:  Arvind P Ganpule; Rohan S Batra; Nitiraj B Shete; Abhishek G Singh; Ravindra B Sabnis; Mahesh R Desai
Journal:  Am J Clin Exp Urol       Date:  2021-06-15

Review 4.  Nocturia through the menopausal transition and beyond: a narrative review.

Authors:  Kim Pauwaert; An-Sofie Goessaert; Lynn Ghijselings; Thomas F Monaghan; Herman Depypere; Karel Everaert
Journal:  Int Urogynecol J       Date:  2021-01-13       Impact factor: 2.894

Review 5.  Pelvic ultrasound evaluation for benign prostatic hyperplasia: prediction of obstruction.

Authors:  Daniel B Rukstalis
Journal:  Curr Urol Rep       Date:  2014-05       Impact factor: 3.092

6.  Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.

Authors:  E C Alexandre; L R Kiguti; F B Calmasini; F H Silva; K P da Silva; R Ferreira; C A Ribeiro; F Z Mónica; A S Pupo; E Antunes
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

7.  Co-Occurrence of Lower Urinary Tract Symptoms and Frailty among Community-Dwelling Older Men.

Authors:  Scott R Bauer; Rebecca Scherzer; Anne M Suskind; Peggy Cawthon; Kristine E Ensrud; William A Ricke; Kenneth Covinsky; Lynn M Marshall
Journal:  J Am Geriatr Soc       Date:  2020-08-21       Impact factor: 5.562

8.  Lower urinary tract symptoms and incident functional limitations among older community-dwelling men.

Authors:  Scott R Bauer; Peggy M Cawthon; Kristine E Ensrud; Anne M Suskind; John C Newman; Howard A Fink; Kaiwei Lu; Rebecca Scherzer; Andrew R Hoffman; Kenneth Covinsky; Lynn M Marshall
Journal:  J Am Geriatr Soc       Date:  2021-12-24       Impact factor: 5.562

9.  Association of Lower Urinary Tract Symptom Severity with Kidney Function among Community Dwelling Older Men.

Authors:  Scott R Bauer; Rebecca Scherzer; Shoujun Zhao; Benjamin N Breyer; Stacey A Kenfield; Michael Shlipak; Lynn M Marshall
Journal:  J Urol       Date:  2020-06-28       Impact factor: 7.450

10.  Anticholinergics combined with alpha-blockers for treating lower urinary tract symptoms related to benign prostatic obstruction.

Authors:  Ran Pang; Xin-Yao Zhou; Xiangling Wang; Bin Wang; Xue-Lai Yin; Hai Bo; Jae Hung Jung
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.